CARDIOVASCULAR DISORDERS IN PATIENTS WITH PARKINSON’S DISEASE
Even if in the last decade, the non-motor symptomatology of Parkinson disease was studied, a more careful investigation of cardiovascular disorders associated with PD remained of lesser interest. The listing and accounting of non-motor signs of PD has entered in current clinical practice, the NMS QUEST questionnaire, developed in 2006 is currently available to all clinicians. Among the non-motor signs of PD, of cardiovascular signs only ortostatic hypotension and changes in blood pressure are mentioned. The cardiovascular disorders of PD pacients is nevertheless obvious in clinical practice, but was generally considered as being explainable as a commorbidity related to the age of the patients and the high incidence of these diseases. There are elements that sustain a more careful analysis of cardiovascular disorders in PD patients. Older studies have shown an increased risk in valvular disease in patients treated with pergolides and cabergolides. More recently, it was proven that there is an increase in the risk of abnormal valvular regurgitation of 2,33 in patients treated with bromocriptine5 compared to those that received no treatment. On the other hand, dihydropiridine calcium channel blockers were associated with a decrease in PD relative risk of 29% (RR) = 0.71, 95% confidence interval (CI): 0.60, 0.82)4. Symptomatic arterial hypotension has a 20% prevalence in patients with PD. Sympatic denerving of the heart is documented in Lewy body dementia by scintigraphy and through morfopathological studies5. All these data suggest that there is a possible influence of PD on the heart and the vascular system. The present paper intends to investigate the association between cardiovascular disorders at patients with PD that were under ambulatory neurological surveillance at the Neurology 1 Clinic.